1. Scrip

CLL Sector Heats Up, AbbVie/Roche Upbeat About First-Line Venetoclax Combo

 
• By John Davis

Positive top-line data on use of an AbbVie/Genentech's venetoclax combination as a first-line chronic lymphocytic leukemia therapy heralds stiffer competition in the therapeutic sector in the years to come.  

Cycling
CLL market is likely to see increased competition • Source: Shutterstock.

AbbVie Inc. and Roche have announced their first-in-class BCL-2 inhibitor, venetoclax (Venclexta in the US, Venclyxto in Europe) has met the primary endpoint in a German clinical study which could allow the drug's indications to be extended to the first-line treatment of chronic lymphocytic leukemia (CLL), a therapeutic sector shaping up to become notably competitive.

The use of a combination of venetoclax and Roche/Biogen Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas